ArticleBMC cancer2026
The tumor-suppressive function of the unique H domain of FCGBP and its potential as a therapeutic target in colorectal cancer.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundColorectal cancer (CRC) is a major global health issue, characterized by high incidence and mortality rates. This study aims to further elucidate the function of H domain of Fc fragment of IgG binding protein (HFCGBP), as a candidate tumor suppressor gene, in the progression of CRC and its clinical implications.
methodsA comprehensive methodological approach was employed, encompassing the collection of clinical samples, proliferation and migration assays, immunohistochemistry, and in-depth data analysis.
resultsThe downregulation of FCGBP expression was significant negatively correlated with tumor stage and grade in CRC tissues. Importantly, the overexpression of HFCGBP in CRC cells resulted in a notable inhibition of cell proliferation and migration, highlighting its potential as a therapeutic target. Combined with bioinformatic analysis of RNA-seq, the key signaling pathways modulated by HFCGBP, such as neuroactive ligand-receptor interaction and platelet activation, were identified, thereby offering valuable insights into its regulatory mechanisms. Furthermore, the analysis of TCGA and Gene Expression Omnibus (GEO) databases further confirmed the reduced expression of FCGBP in various tumor types, with a particular focus on CRC, reinforcing its potential as a prognostic biomarker. It underscores the crucial role of HFCGBP in CRC and its promising potential as a therapeutic target.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.